China's BeiGene prices $200m follow-on
Chinese biopharmaceutical company BeiGene has net $200m from a follow-on public offering of American Depositary Shares (ADSs).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: